- Medicare will cover the Alzheimer’s drug Aduhelm only for clinical trials, despite the Food and Drug Administration (FDA) approving the drug for some 1.5 million people. Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure said the decision was made based on data showing the drug has serious safety risks and may not help patients. She also said that “the vast majority” of comments submitted to CMS were in favor of “really limiting coverage of Aduhelm to a really controlled space where we could continue to evaluate its appropriateness for the Medicare population.” (Articles here, here, here, and here)
April 8, 2022
Payers